Research programme: monoclonal antibodies - Alder Biopharmaceuticals

Drug Profile

Research programme: monoclonal antibodies - Alder Biopharmaceuticals

Alternative Names: ALD 1613; ALD 1910

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator Alder Biopharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Corticotropin receptor antagonists; Pituitary adenylate cyclase-activating polypeptide receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Migraine
  • Discontinued Congenital adrenal hyperplasia; Pituitary ACTH hypersecretion

Most Recent Events

  • 26 Jul 2016 Preclinical trials in Migraine in USA (Parenteral)
  • 26 Jul 2016 Discontinued - Preclinical for Pituitary ACTH Hypersecretion in USA (Parenteral)
  • 26 Jul 2016 Discontinued - Preclinical for Congenital adrenal hyperplasia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top